Overview

A Single and Repeated Dose Escalation of RBD1016 in Subjects With Chronic Hepatitis B Virus (HBV) Infection

Status:
Active, not recruiting

Trial end date:
2024-05-01

Target enrollment:

Participant gender:

Summary

This is a randomized, double-blind, placebo-controlled, single (Part A) and repeated dose (Part B) escalation, phase I clinical study to evaluate the safety, pharmacokinetics (PK) and preliminary pharmacodynamics (PD) of RBD1016 in subjects with chronic HBV infection.

Phase:

Phase 1

Details

Lead Sponsor:

Suzhou Ribo Life Science Co. Ltd.

Treatments:

Entecavir